Ізраїль - англійська - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib - film coated tablets - erlotinib 150 mg - erlotinib - non-small cell lung cancer (nsclc):tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.tarceva is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy.tarceva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer:tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Ізраїль - англійська - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib - film coated tablets - erlotinib 150 mg - erlotinib - non-small cell lung cancer (nsclc):tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.tarceva is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy.tarceva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer:tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Ізраїль - англійська - Ministry of Health

bayer israel ltd - ethinylestradiol; gestodene - coated tablets - ethinylestradiol 0.020 mg; gestodene 0.075 mg - gestodene and estrogen - oral contraceptive.

Ізраїль - англійська - Ministry of Health

unipharm ltd, israel - sertraline as hydrochloride - coated tablets - sertraline as hydrochloride 100 mg - sertraline - for the treatment of symptoms of depression in patients with or without a history of mania. following satisfactory respose, continuation with sertaline therapy is effective in preventon relapse of the initial episode of depression or recurrence of further depressive episodes.

Ізраїль - англійська - Ministry of Health

unipharm ltd, israel - sertraline as hydrochloride - coated tablets - sertraline as hydrochloride 50 mg - sertraline - for the treatment of symptoms of depression in patients with or without a history of mania. following satisfactory respose, continuation with sertaline therapy is effective in preventon relapse of the initial episode of depression or recurrence of further depressive episodes.

Ізраїль - англійська - Ministry of Health

bayer israel ltd - rivaroxaban micronized - film coated tablets - rivaroxaban micronized 15 mg - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Ізраїль - англійська - Ministry of Health

bayer israel ltd - rivaroxaban micronized - film coated tablets - rivaroxaban micronized 15 mg - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Ізраїль - англійська - Ministry of Health

bayer israel ltd - rivaroxaban micronized - film coated tablets - rivaroxaban micronized 20 mg - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Ізраїль - англійська - Ministry of Health

bayer israel ltd - rivaroxaban micronized - film coated tablets - rivaroxaban micronized 20 mg - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Ізраїль - англійська - Ministry of Health

unipharm trading ltd, israel - everolimus - tablets - everolimus 10 mg - everolimus - evetor is indicated for:- treatment of patients with sega associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection. the effectiveness of evetor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated. - treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease. the safety and effectiveness of evetor in the treatment of patients with carcinoid tumors have not been established. - treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non – steroidal aromatase inhibitor. - treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (tsc), not requiring immediate surgery. the effectiveness of evetor in treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. further follow-up of patients is required to determine long-term outcomes. - treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vegf-targeted therapy.- treatment of unresectable, locally advanced or metastatic, well-differentiated (grade 1 or grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.